Funding for this research was provided by:
National Major Scientific and Technological Special Project (2011ZX09101-003-01)
National High Technology Research and Development Program of China (2006AA090501)
Received: 2 July 2020
Accepted: 2 September 2020
First Online: 14 September 2020
Ethics approval and consent to participate
: The trial protocol was approved by the Ethics Review Board of Shanghai Mental Health Center (Shanghai, China). The trial protocol was approved by the Institutional Review Boards of all participating sites. All participants or their representatives provided written informed consent before participation in the trial.
: All authors approved the final version of the manuscript for submission.
: Shifu Xiao has been a provisional consultant of Pfizer, Lilly, Novartis, GSK, Johnson & Johnson, Lundbeck, and Green Valley and received honorariums. Kewei Chen was a paid consultant and a full-time employee of Shanghai Green Valley Pharmaceutical Co., Ltd. at the time the FDG-PET data was analyzed, and the time the manuscript was prepared respectively. Currently, he is a full-time employee of Banner Health to which Banner Alzheimer’s Institute belongs, and serves as a paid consultant to Shanghai Green Valley Pharmaceutical Co., Ltd. Xianliang Xin is a full-time employee of the Shanghai Green Valley Pharmaceutical Co Ltd. Part of the results of this paper was presented at the 7th Clinical Trials Conference on Alzheimer’s Disease (CTAD) November 20–22, 2014, Philadelphia, PA, USA.